AMGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 20.83%. Amgen, Inc.'s return on equity of 102.03% beat Johnson & Johnson's return on equity of 34.46%.

Amgen, Inc. has a consensus price target of $350.04, signalling downside risk potential of -6.6%. On the other hand Johnson & Johnson has an analysts' consensus of $232.50 which suggests that it could fall by -4.12%. Given that Amgen, Inc. has more downside risk than Johnson & Johnson, analysts believe Johnson & Johnson is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.465, which suggesting that the stock is 53.492% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.58%. Johnson & Johnson offers a yield of 2.12% to investors and pays a quarterly dividend of $1.30 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Amgen, Inc.'s net income of $1.3B is lower than Johnson & Johnson's net income of $5.1B. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.33x while Johnson & Johnson's PE ratio is 21.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.53x versus 6.25x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 34.4%. Amgen, Inc.'s return on equity of 102.03% beat Eli Lilly & Co.'s return on equity of 104.39%.

Amgen, Inc. has a consensus price target of $350.04, signalling downside risk potential of -6.6%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Eli Lilly & Co. has higher upside potential than Amgen, Inc., analysts believe Eli Lilly & Co. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.465, which suggesting that the stock is 53.492% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.58%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Amgen, Inc.'s net income of $1.3B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.33x while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.53x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 18.06%. Amgen, Inc.'s return on equity of 102.03% beat Merck & Co., Inc.'s return on equity of 39.63%.

Amgen, Inc. has a consensus price target of $350.04, signalling downside risk potential of -6.6%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 3.06%. Given that Merck & Co., Inc. has higher upside potential than Amgen, Inc., analysts believe Merck & Co., Inc. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.465, which suggesting that the stock is 53.492% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.58%. Merck & Co., Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.85 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Amgen, Inc.'s net income of $1.3B is lower than Merck & Co., Inc.'s net income of $3B. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.33x while Merck & Co., Inc.'s PE ratio is 16.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.53x versus 4.72x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 13.47% compared to Amgen, Inc.'s net margin of 21.74%. Amgen, Inc.'s return on equity of 102.03% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Amgen, Inc. has a consensus price target of $350.04, signalling downside risk potential of -6.6%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.58%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Amgen, Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Amgen, Inc..

Amgen, Inc. has a beta of 0.465, which suggesting that the stock is 53.492% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Amgen, Inc. has a quarterly dividend of $2.52 per share corresponding to a yield of 2.58%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Amgen, Inc. pays 66.92% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen, Inc. quarterly revenues are $9.9B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Amgen, Inc.'s net income of $1.3B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Amgen, Inc.'s price-to-earnings ratio is 26.33x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen, Inc. is 5.53x versus 5.90x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.